
NuVasive, Inc. – NASDAQ:NUVA
NuVasive stock price monthly change
NuVasive stock price quarterly change
NuVasive stock price yearly change
NuVasive key metrics
Market Cap | 2.08B |
Enterprise value | 2.97B |
P/E | 56.03 |
EV/Sales | 2.47 |
EV/EBITDA | 13.73 |
Price/Sales | 1.84 |
Price/Book | 2.55 |
PEG ratio | 0.34 |
EPS | 0.54 |
Revenue | 1.22B |
EBITDA | 189.78M |
Income | 28.45M |
Revenue Q/Q | 2.36% |
Revenue Y/Y | 4.43% |
Profit margin | 3.36% |
Oper. margin | 6.94% |
Gross margin | 72% |
EBIT margin | 6.94% |
EBITDA margin | 15.48% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeNuVasive stock price history
NuVasive stock forecast
NuVasive financial statements
Sep 2022 | 295.28M | -1.97M | -0.67% |
---|---|---|---|
Dec 2022 | 305.44M | 24.07M | 7.88% |
Mar 2023 | 307.71M | -1.01M | -0.33% |
Jun 2023 | 317.78M | 7.36M | 2.32% |
Sep 2022 | 2174945000 | 1.34B | 61.74% |
---|---|---|---|
Dec 2022 | 2224505000 | 1.35B | 60.94% |
Mar 2023 | 2167154000 | 1.29B | 59.69% |
Jun 2023 | 2089550000 | 1.19B | 57.29% |
Sep 2022 | 54.25M | -39.52M | -496K |
---|---|---|---|
Dec 2022 | 46.77M | -40.97M | 1.57M |
Mar 2023 | 1.97M | -35.14M | -34.90M |
Jun 2023 | 36.51M | -40.09M | -96.80M |
NuVasive alternative data
Aug 2023 | 3,000 |
---|---|
Sep 2023 | 3,000 |
Oct 2023 | 3,000 |
Nov 2023 | 3,000 |
Dec 2023 | 3,000 |
Jan 2024 | 3,000 |
Feb 2024 | 3,000 |
Mar 2024 | 3,000 |
Apr 2024 | 3,000 |
May 2024 | 3,000 |
Jun 2024 | 3,000 |
Jul 2024 | 3,000 |
NuVasive other data
Period | Buy | Sel |
---|---|---|
May 2021 | 0 | 5607 |
Jun 2021 | 0 | 10000 |
Mar 2022 | 0 | 5000 |
Apr 2022 | 0 | 5000 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Option | HARBAUGH MATTHEW K officer: EVP and .. | RSUs | 12,190 | N/A | N/A | ||
Option | SISITSKY NATHANIEL officer: SVP & Ge.. | RSUs | 5,333 | N/A | N/A | ||
Option | WOLF DALE A. officer: SVP, Global Operations | RSUs | 4,572 | N/A | N/A | ||
Option | FARRINGTON MICHAEL officer: SVP, People and Culture | RSUs | 1,905 | N/A | N/A | ||
Option | FARRINGTON MICHAEL officer: SVP, People and Culture | Common Stock | 1,905 | N/A | N/A | ||
Option | WOLF DALE A. officer: SVP, Global Operations | Common Stock | 4,572 | N/A | N/A | ||
Option | ROSENBAUM MARC W. officer: Chief Accounting Officer | RSUs | 1,829 | N/A | N/A | ||
Option | ROSENBAUM MARC W. officer: Chief Accounting Officer | Common Stock | 1,829 | N/A | N/A | ||
Option | SISITSKY NATHANIEL officer: SVP & Ge.. | Common Stock | 5,333 | N/A | N/A | ||
Option | BARRY JAMES CHRISTOPHER director, officer: Chief Execut.. | RSUs | 34,284 | N/A | N/A |
Patent |
---|
Grant Filling date: 23 Oct 2020 Issue date: 20 Sep 2022 |
Grant Filling date: 25 Feb 2020 Issue date: 20 Sep 2022 |
Grant Filling date: 20 Aug 2019 Issue date: 9 Aug 2022 |
Application Filling date: 25 Apr 2022 Issue date: 4 Aug 2022 |
Application Filling date: 12 Apr 2022 Issue date: 4 Aug 2022 |
Grant Filling date: 21 Apr 2020 Issue date: 2 Aug 2022 |
Grant Filling date: 5 Sep 2019 Issue date: 2 Aug 2022 |
Grant Filling date: 6 Jun 2019 Issue date: 2 Aug 2022 |
Application Filling date: 15 Apr 2022 Issue date: 28 Jul 2022 |
Grant Filling date: 23 Oct 2019 Issue date: 19 Jul 2022 |
Quarter | Transcript |
---|---|
Q2 2023 2 Aug 2023 | Q2 2023 Earnings Call Transcript |
Q1 2023 10 May 2023 | Q1 2023 Earnings Call Transcript |
Q4 2022 22 Feb 2023 | Q4 2022 Earnings Call Transcript |
Q3 2022 9 Nov 2022 | Q3 2022 Earnings Call Transcript |
Insider | Compensation |
---|---|
Mr. J. Christopher Barry (1973) Chief Executive Officer & Director | $1,440,000 |
Mr. Matthew K. Harbaugh (1970) Executive Vice President & Chief Financial Officer | $1,020,000 |
Mr. Nathaniel B. Sisitsky Esq. (1974) Senior Vice President, Gen. Counsel & Corporation Sec. | $594,940 |
NuVasive: An Excellent Growth Story In Spine Surgery
Globus Medical Showing Some Reacceleration And Innovation Can Continue To Drive Growth
NuVasive: Prepared To Endure Current Headwinds
NuVasive's Turnaround Story Needs A Boost From Better Results
Globus Medical Continues To Flex Its Innovation Muscles To Drive Share Growth
NuVasive: A Compelling And Comprehensive Spine Surgery Play
The Stocks To Focus On Today
The Top Stocks You Can Buy Now
Stocks With The Best History Of Beating Estimates
-
When is NuVasive's next earnings date?
Unfortunately, NuVasive's (NUVA) next earnings date is currently unknown.
-
Does NuVasive pay dividends?
No, NuVasive does not pay dividends.
-
How much money does NuVasive make?
NuVasive has a market capitalization of 2.08B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 5.53% to 1.2B US dollars.
-
What is NuVasive's stock symbol?
NuVasive, Inc. is traded on the NASDAQ under the ticker symbol "NUVA".
-
What is NuVasive's primary industry?
Company operates in the Healthcare sector and Medical - Devices industry.
-
How do i buy shares of NuVasive?
Shares of NuVasive can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are NuVasive's key executives?
NuVasive's management team includes the following people:
- Mr. J. Christopher Barry Chief Executive Officer & Director(age: 52, pay: $1,440,000)
- Mr. Matthew K. Harbaugh Executive Vice President & Chief Financial Officer(age: 55, pay: $1,020,000)
- Mr. Nathaniel B. Sisitsky Esq. Senior Vice President, Gen. Counsel & Corporation Sec.(age: 51, pay: $594,940)
-
How many employees does NuVasive have?
As Jul 2024, NuVasive employs 3,000 workers.
-
When NuVasive went public?
NuVasive, Inc. is publicly traded company for more then 21 years since IPO on 13 May 2004.
-
What is NuVasive's official website?
The official website for NuVasive is nuvasive.com.
-
Where are NuVasive's headquarters?
NuVasive is headquartered at 7475 Lusk Boulevard, San Diego, CA.
-
How can i contact NuVasive?
NuVasive's mailing address is 7475 Lusk Boulevard, San Diego, CA and company can be reached via phone at 858 909 1800.
NuVasive company profile:

NuVasive, Inc.
nuvasive.comNASDAQ
3,000
Medical - Devices
Healthcare
NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary implant device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California.
San Diego, CA 92121
CIK: 0001142596
ISIN: US6707041058
CUSIP: 670704105